Volume 14, Issue 1 (3-2026)                   JoMMID 2026, 14(1): 58-64 | Back to browse issues page

Ethics code: IR.SSU.MEDICINE.REC.1402.254

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Soleymani S, Samet M, Namiranian N, Aghaei Meybodi F A. Bacterial and Fungal Co-Infections in COVID-19: Mortality and Infection Control in Yazd, Iran. JoMMID 2026; 14 (1) :58-64
URL: http://jommid.pasteur.ac.ir/article-1-726-en.html
Bacterial and Fungal Co-Infections in COVID-19: Mortality and Infection Control in Yazd, Iran
Salameh Soleymani , Mohammad Samet , Nasim Namiranian , Fatemeh al-Sadat Aghaei Meybodi *
Department of Internal Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Abstract:   (530 Views)
Introduction: Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), bacterial co-infections have become an important concern in the clinical management of coronavirus disease 2019 (COVID-19), especially in patients with severe illness, as they contribute to increased morbidity and mortality. This study aimed to investigate the epidemiological and clinical characteristics of bacterial co-infections in hospitalized patients with severe COVID-19 in Yazd Province, Iran. Methods: In this retrospective descriptive-analytical study, 110 adult patients with reverse transcription polymerase chain reaction-confirmed COVID-19 (RT-PCR) and positive blood cultures, hospitalized at Shahid Sadoughi Hospital between February 2020 and February 2023, were evaluated. Data were extracted from electronic health records and patient files, including demographic information, comorbidities, clinical symptoms, complications, oxygen therapy details, admission oxygen saturation, duration of hospitalization, isolated bacterial or fungal pathogens, treatments, laboratory results, and clinical outcomes. Blood culture findings were independently reviewed by two investigators, and any discrepancies were resolved through consensus or by a third reviewer to minimize bias. Statistical analysis was performed using IBM SPSS Statistics version 22.0. The normality of continuous variables was assessed using the Shapiro-Wilk test, and data were presented as mean ± standard deviation (SD) or median (interquartile range [IQR]), as appropriate. Group comparisons were conducted using t-test or Mann-Whitney U test for continuous variables, and chi-square (χ²) or Fisher's exact tests for categorical variables. A P-value < 0.05 was considered statistically significant. Results: Patients had a mean age of 64.94 ± 18.86 years, of whom 52.7% were male. Fever and shortness of breath were the most common symptoms, and hypertension was the most prevalent comorbidity. Pseudomonas aeruginosa (37.3%) and Klebsiella pneumoniae (29.1%) were the most frequently isolated pathogens, with Gram-negative bacteria accounting for 74.5% of infections. The mortality rate among patients with positive blood cultures was 28.2%. Conclusion: Bacterial co-infections are more common in severe COVID-19 cases admitted to the intensive care unit (ICU) and are associated with prolonged hospital stays. Appropriate antibiotic stewardship and strict infection control measures are essential to prevent secondary infections and limit the spread of drug-resistant bacteria in healthcare settings.
 
Keywords: COVID-19, Bacterial co-infections, SARS-CoV-2, Secondary infections
Full-Text [PDF 424 kb]   (140 Downloads)    
Type of Study: Original article | Subject: Infectious diseases and public health
Received: 2025/04/12 | Accepted: 2026/02/21 | Published: 2026/03/17
References
1. He S, Liu W, Jiang M, Huang P, Xiang Z, Deng D, et al. Clinical characteristics of COVID-19 patients with clinically diagnosed bacterial co-infection: a multi-center study. PLoS One. 2021; 16 (4): e0249668.
2. Razavi R, Namiranian N, Samet M, Aghaei Meybodi F. Investigating the therapeutic effect of β-interferon and methylprednisolone on COVID-19 patients' outcome: a non-randomized, double-blind, controlled study. 2022; 30 (143): 486-92.
3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395 (10223): 507-13.
4. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020; 39 (5): 355-68.
5. Wu CP, Adhi F, Highland K. Recognition and management of respiratory co-infection and secondary bacterial pneumonia in patients with COVID-19. Cleve Clin J Med. 2020; 87 (11): 659-63.
6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395 (10229): 1054-62.
7. Alosaimi B, Naeem A, Hamed ME, Alkadi HS, Alanazi T, Al Rehily SS, et al. Influenza co-infection associated with severity and mortality in COVID-19 patients. Virol J. 2021; 18 (1): 127-35.
8. Lv Z, Cheng S, Le J, Huang J, Feng L, Zhang B, et al. Clinical characteristics and co-infections of 354 hospitalized patients with COVID-19 in Wuhan, China: a retrospective cohort study. Microbes Infect. 2020; 22 (4-5): 195-9.
9. Barry M, AlMohaya A, AlHijji A, Akkielah L, AlRajhi A, Almajid F, et al. Clinical characteristics and outcome of hospitalized COVID-19 patients in a MERS-CoV endemic area. J Epidemiol Glob Health. 2020; 10 (3): 214-21.
10. Asmarawati TP, Rosyid AN, Suryantoro SD, Mahdi BA, Windradi C, Wulaningrum PA, et al. The clinical impact of bacterial co-infection among moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya. F1000Research. 2021;10: 113-28.
11. Abad CL, Sandejas JCM, Poblete JB, Malundo AFG, Salamat MSS, Alejandria MM. Bacterial coinfection and antimicrobial use among patients with COVID-19 infection in a referral center in the Philippines: a retrospective cohort study. IJID Reg. 2022; 4: 123-30.
12. Ramadan HK-A, Mahmoud MA, Aburahma MZ, Elkhawaga AA, El-Mokhtar MA, Sayed IM, et al. Predictors of severity and co-infection resistance profile in COVID-19 patients: first report from Upper Egypt. Infect Drug Resist. 2020: 3409-22.
13. Elabbadi A, Turpin M, Gerotziafas GT, Teulier M, Voiriot G, Fartoukh M. Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia. Infection. 2021; 49 (3): 559-62.
14. Lardaro T, Wang AZ, Bucca A, Croft A, Glober N, Holt DB, et al. Characteristics of COVID-19 patients with bacterial coinfection admitted to the hospital from the emergency department in a large regional healthcare system. J Med Virol. 2021; 93 (5): 2883-9.
15. Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol. 2020; 92 (9): 1549-55.
16. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020; 368 (6490): 473-4.
17. Rothe K, Feihl S, Schneider J, Wallnöfer F, Wurst M, Lukas M, et al. Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship. Eur J Clin Microbiol Infect Dis. 2021; 40 (4): 859-69.
18. Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A, et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infect Dis. 2020; 20 (1): 646-52.
19. Peleg AY, Hooper DC. Hospital-acquired infections due to Gram-negative bacteria. N Engl J Med. 2010; 362 (19): 1804-13.
20. Zhang H, Zhang Y, Wu J, Li Y, Zhou X, Li X, et al. Risks and features of secondary infections in severe and critically ill COVID-19 patients. Emerg Microbes Infect. 2020; 9 (1): 1958-64.
21. Weinstein RA, Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis. 2005; 41 (6): 848-54.
22. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020; 323 (20): 2052-9.
23. Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, et al. Eleven faces of coronavirus disease 2019. Allergy. 2020; 75 (7): 1699-709.
24. Lescure F-X, Bouadma L, Nguyen D, Parisey M, Wicky P-H, Behillil S, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. Lancet Infect Dis. 2020; 20 (6): 697-706.
25. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020; 323 (16): 1612-4.
26. Crotty MP, Akins R, Nguyen A, Slika R, Rahmanzadeh K, Wilson MH, et al. Investigation of subsequent and co-infections associated with SARS-CoV-2 (COVID-19) in hospitalized patients. medRxiv. 2020. doi:10.1101/2020.05.29.20117176.
27. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8 (5): 475-81.
28. Wu HY, Chang PH, Chen KY, Lin IF, Hsih WH, Tsai WL, et al. Coronavirus disease 2019 (COVID-19) associated bacterial coinfection: incidence, diagnosis and treatment. J Microbiol Immunol Infect. 2022; 55 (6): 985-92.
29. Jamnani AN, Montazeri M, Mirzakhani M, Moosazadeh M, Haghighi M. Evaluation of bacterial coinfection and antibiotic resistance in patients with COVID-19 under mechanical ventilation. SN Compr Clin Med. 2022; 4 (1): 19-23.
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.